Any ideas anyone?

Moving up over last few days, is this because more good news is likely? I suspect not, since the co just ann. their canine product is going World-wide (soon), but it might be anticipation of income towards the end of 2007.

The previous wrier is dismissing the appetite suppressant by sugesting humans will resist any attempt...etc.
It is a "magic bullet" IF you can find that part of us that says we are full - but I suspect we may see a situation where our appetite is "remapped" so that the hunger is overcome at lower levels of satisfaction. The problem fat people have is that they have stretched their stomachs - so more food is needed to reach the point of satisfaction....by allowing the satisfaction to come sooner (the amount based on their intake of this replacement food) they will be able to let the stomach reduce in size so they can find goodness in "healthier" foods. Presently they crave fats because these produce the "satisfaction" that we humans crave. It is this "remapping" that I'm hoping is at the foundation of the hoodia commercial product.
(That product has to have a balance of nutrients so anyone that switches to it will remain "balanced" at least until they can eat normally.)
Of course the key to obesity is ...to eat less (to match your exercise, etc), -but this is the goal...not the route. Without help, the route would be extremely painful as few of us can reduce our intake ( say by one third), .....even though it would "probably" be good for us.
The key, IMHO for normal people is alway to keep a little bit of hunger present, that way you know you haven't overdone it. However, what served past generations (the storing of fats for winter) is not needed, since we have food in the shops all-year.
I hold PYM and hope their products are successful, but the market over-hyped the SP until 2005, since when its been under 1 (and often under 50p) which is right IMHO for a co. with no turnover.
I suspect the "biggie" is a few years away, but now might be the time to tuck away.

For whatever reason this has moved up 20% in two days on relatively low volume.
Nearly bought at 40p (bugger!!) but will keep an eye on this, maybe another milestone payment is due or announcement about a product launch?

No need to worry - you can pick them up far lower (32p today) - it seems that late October has brought on the Spectre of Options - - - laughingly said to be part of the incentive-plan - - - So where is mine? - all I recall is the sp slipping and prior promises left hanging in the air.
This sp was well over 1 not that long ago. Promises of a cure for obesity looked good, but they were reluctant to sell anything, preferring to do a deal with Big Pharma - ah yes, but I suspect BP found the stuff was too expensive, so they had to do a deal with a "foodie" - - and as far as I know that has been very silent.
Grr.

EDIT. Dec.'07:-
I read that things are progressing, but there seems to be little interest here/elsewhere, as this is a long-time event. The dog-treatment is doing OK and the Food additive looks to be undergoing trials, still.

Not much to report beyond the EDIT of Dec 07.....
-Apart from a fundraising at 22p - quite dilutive! (March 2008).

-and within two months we are seeing the sp matching the Discounted Rights Issue......Oh no, is this another bad investment?

MM's push the sp up 3% on zero volume - 17p to buy - Will I?

Hey-Ho and up they go,
Ho-Hum and Down they come.

Hello, PYM,...
Let's know what you are doing with this( Rights issue at 22p), money - is it holiday-break time, I wonder?

PYM received notice of termination of employment contract
from Daryl Rees, Chief Executive Officer,
and Piers Morgan, Chief Financial Officer.
(sp is down 15% on zero volume - MM's playing with us.)


- FWIW - To lose one Director is carelessness, but TWO is a disaster.
CEO and FD both walk - could this be the beginning of a real bust-up at this serial-loser?
+They had 22p(Rights) from shareholders and this is now 9p - Grr.
EDIT (17Nov08)- 7.5p to Buy today after a sale of 3k, it falls 25% - then, later Buys=3k qnd it's up to +30% - How can this Full-Mkt stock move so much on just 3k deals?I Guess at these levels this is a Bargain, but I'm fearful this Management has been smoking the stuff (-oops!).
EDIT(19Nov08)- up 25% on zero trades -Huh!
EDIT(9Dec08)- down 20% on Sales just over 1k.
EDIT(10Dec08)- up 13% on zero volume, [4.5--6.5p]
EDIT (30Jan09) - down 14% on zero-volume (3.75p,mid. what a Shower!)
EDIT(20May09) - up on general Market rise; then down today - losses increase - isn't this a hopeless business (despite the Fido-treatment.).
EDIT-(12Jn09)- Recent results look pertty dire - in effect a tiny turnover and a mildly staggering loss! Yikes! What it is saying is that for the last 10-years we've been asleep, hoping something would turn up. What I continue to wonder about is why Hoodia isn't a stonking success... does it taste really foul? - - - or is it easy to "overdose" on it? - - What would be the OD effect? - surely any medicine causes difficulties if you take all the tablets in one hit?
EDIT(8Jy09)-a Buy of 225(plus charges) pushes the sp 11% - Oh deary.
EDIT (13Oct09)-rise of 22% on No News, yet Buys are 8x Sells, for a change.
EDIT(14Oct09)- Ah yes, Drug success, which we only know today.[=up 330%!!! on Buys barely 2x Sells, IMHO this is MM's ...making Hay].#
EDIT (15Oct09)-oddly the sp is marked down, yet the Buys are nearly 1/3 more than Sells...Odd.
EDIT (19Oct09)-Buys?Sells evens, yet MM's push sp 11%, prob on Broker 50p assumption . . . er? [ 24p today]

Studies offer hope for Phytopharm Parkinson's treatment

KBC Peel Hunt doubles Phytopharm TP to 50p on Cogane results, keeps buy

WOW---who was lucky enough to be holding this one today! Looks as though all pxs fans have found another star and it can go into your isa. I'm in for a few before the US open. It might fall back but the treatment/success looks good.

Its the first 'doubler' in a day I've had since those heady tech days!

UPDATE: Phytopharm Shares Soar On Early Cogane Promise





(Adds detail on drug's potential, analyst comment, stock rating)


By Jason Douglas
Of DOW JONES NEWSWIRES

LONDON -(Dow Jones)- Shares in drug maker Phytopharm PLC (PYM.LN) more than quadrupled Wednesday after it said its experimental Parkinson's disease treatment Cogane showed promise in two early-stage studies.

Phytopharm said a study funded by the Michael J. Fox Foundation, a Parkinson's research charity founded by the Hollywood actor, showed use of Cogane led to a 43% reduction in Parkinson's symptoms among monkeys given a drug to replicate those symptoms.

This type of study in monkeys is considered the gold-standard model for assessing experimental Parkinson's medicines before testing them on humans, according to Jonathan Brochtie, a senior scientist at Toronto West Hospital who conducted the study.

"Cogane holds the promise to be the first in a new class of treatments," he said.

A second study in a small number of healthy human volunteers showed Cogane was safe and also demonstrated some evidence of pharmacological activity, Phytopharm said.

The firm now plans a phase II clinical study of Cogane in patients next year.

At 1435 GMT, shares in Phytopharm were 18.87 pence higher at 25 pence, making it the biggest riser in a 0.5% higher FTSE Fledging index.

Cogane is far from starting the big human trials needed to win regulatory approval. But Paul Cuddon, an analyst at Phytopharm's broker KBC Peel Hunt, said the results of these trials show real promise because this type of primate trial has been shown to be "highly predictive" of a similar response in humans. He rates the stock "buy" and Wednesday upped his price target to 50 pence from 25 pence.

It has been a tough year for Phytopharm. The stock has languished ever since a planned collaboration with Unilever NV (UNA.AE) to develop a Slim Fast diet drink based on the hoodia plant was called off last November.

Robin Davison, an analyst at Edison Investment Research, said Wednesday's share price rise shows investors are still interested in Phytopharm.

"The company has shown it still has a drug, where previously people had written them off," said Davison.

It might also signal renewed interest in the U.K. small-cap drug sector, which has suffered from a dearth of funds and several company failures, he added.

Company Web site: www.phytopharm.com

IMHO, ....you can forget the 4x jump in sp - it was the ONLY good news (any ?) we've had since the shares were 1....way back when they thought their product would cure obesity....can anyone remember how many years that was ago..
. . . . . . . . . . . . . . Clearly rubbish, it limps on . . . . . . . . . . . .

Now they have the nerve to build-up prospects of untold wealth on the basis of a phI result (ie it doen't kill you).....and this fundraising will be hugely dilutive.....

I really wonder if this isn't "...more of the same..." - - - I really object to phrases like "...potentially addresses a large and as of yet unmet medical need..." - this adds nothing to the effacy of their product, it is IMHO mere puff, or at worse it's ramping, - even before the Trials are mid-way. Not the expected PR from a full-list company.
=Grr.
FWIW, I note the Co says the money will be used for various operational uses as well as PhII trials - and the risk of failure is huge even from the start of PhII.
Maybe wait for the documents . . . .
DYOR

pym despite its problems in the past has huge potential for cognane - potential market of billions - so far trials gone well - also has other products - just need some more patience - personally i am going to give pym to end 2010 to improve sp with hopefully decent rns throughout the year - should reach 50p imo easily - slow share clinical trials etc take time - more patience needed - sorry for anyone who bought in 30p+ - i will be taking my 8 for 3 placement / open offer

gibby, are you sure - for there is "no evidence" ( ie "yet") that their product works.
However, there is evidence the sp has been pushed up prior to the RNS - and I don't like this - just review the volume from a week prior....

I accept yr timescale - "end-of2010" - in a year there should be some "news" - but it won't be very much to impress current holders who have been massivly diluted by this Offer.

Furthermore, I recall reading that when a stock is "hot" the City can raise all the funds req'd. Only when it might "stick" are the investors asked....

Maybe we'll have to Agree to Disagree; as I'm tempted to ignore this Attractive Offer.....and maybe put the money to a nice present to Me, like a 12MP digital Camera......and a nice holiday into the sun, before I can't move for Carbon-Permits.

hangon - i agree its a risk but arent all shares - i am actually only trading with pym from other share profits so if it goes belly up the worst i will do is off set the loss against my cgt - trust me i know pyms history so aware of risk, but invesco for as an example have taken up their full entitlement through their iaml vechicle & if its good enough for them + my research its good enough for me - they have also guaranteed to take up any oo shares not taken up by pi's i believe - but will see how 2010 goes - i am very confident but happy to eat huge slice of humble pie if i am wrong - any how i hope your dealing goes well and profitable where ever you may invest - pym are not my only investment - lots of opportunities out there as i am sure you are aware - GL

Presents data at XVIII WFN World Congress


GODMANCHESTER, Cambridgeshire, U.K. (14 December 2009) - Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announces that Dr Jonathan Brotchie will present data from a "gold-standard" non-clinical study of Cogane, a promising novel oral treatment for Parkinson's disease, at the 50th WFN World Congress on Parkinson's Disease and Related Disorders, which is taking place in Miami from 13 - 16 December.


The outcome of this study, an overall 43% decrease in parkinsonian symptoms over 18 weeks administration of Cogane, was first reported by Phytopharm on 14 October 2009 along with the results of a successful safety, tolerability and pharmacokinetic trial in healthy volunteers and patients with Parkinson's disease.


Dr Brotchie, a senior scientist at Toronto Western Hospital, who conducted the trials, is a recognised expert in the field of Parkinson's disease and runs one of the world's premier research laboratories for the identification of novel treatments, diagnostics and cures for Parkinson's disease and related disorders.

Isn't it heartening that so much good-news comes at a time when the company is diluting L-T investors and ripping-off new ones? Folk could have bought into this company at any time during the year when there was zippo on the Newsfront...? I wonder if the next 12-months will be a mirror...?

I didn't take-up my placing shares, 'cos I think we was manipulated....the sp graph says it all. See the peaking just days before the placing was ann.

DYOR and bear in mind that the trumpeted product Trial is years away from commercialisation....indeed they'll have to rejig their scratchless-doggy cream in preparation for a further round of Funding, not for Trials....but to service the gardens and upgrade the lawns at their country seat.
Hoodia . . . . I should Coco.
This has been a woeful investment.
EDIT (22Dec09)-up a tad, at 11.5p but Rights takeup is only 51% - yuk.
EDIT (28May2010)-down further today mkes me wonder if this isn't dead? Gibby hopes for a buy-out. Well Hoodia has shown no signs of success...and without that, what's left?
EDIT (22Jy2010)- Oh deary, Director lathered by Options of 1.7million at zero cost (for now), priced below today's price 8p.......exercisable for the next 5years (I thk).Win-Win or what? This stock is a disgrace IMHO.

hangon - you are semi correct - dont all companies manipulate the sp - some far worse than this - but your post is also amusing- i'm not worried if next stage goes well sp will impprove very much - wouldnt ne surprised if a major pharm eventually bought out ptm - probably why invesco have a large stake in pym through one of their subsidaries - until invesco naff off i will be staying - gl

Interim Management Statement.

Phytopharm receives USA regulatory approval to begin Phase II clinical trial of Cogane